Q4 EPS Estimates for Journey Medical Raised by HC Wainwright

Journey Medical Corporation (NASDAQ:DERM) – Equities researchers at HC Wainwright raised their Q4 2026 EPS estimates for Journey Medical in a research note issued to investors on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the company will earn $0.22 per share for the quarter, up from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical’s current full-year earnings is $0.19 per share.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analysts’ expectations of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Monday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $13.00.

Journey Medical Stock Up 1.8%

DERM stock opened at $5.13 on Friday. The stock has a market capitalization of $140.20 million, a P/E ratio of -10.91 and a beta of 1.03. Journey Medical has a 52 week low of $4.31 and a 52 week high of $9.56. The firm has a 50-day simple moving average of $6.64 and a 200-day simple moving average of $7.50. The company has a quick ratio of 1.53, a current ratio of 1.79 and a debt-to-equity ratio of 0.79.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DERM. Wasatch Advisors LP raised its position in Journey Medical by 62.1% in the first quarter. Wasatch Advisors LP now owns 2,133,370 shares of the company’s stock valued at $10,006,000 after purchasing an additional 817,095 shares during the period. Invesco Ltd. purchased a new stake in shares of Journey Medical in the 4th quarter valued at approximately $127,000. XTX Topco Ltd acquired a new position in shares of Journey Medical in the 4th quarter worth approximately $126,000. Ikarian Capital LLC purchased a new position in shares of Journey Medical during the 4th quarter worth approximately $1,939,000. Finally, Occudo Quantitative Strategies LP increased its holdings in Journey Medical by 22.3% in the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company’s stock valued at $146,000 after purchasing an additional 3,443 shares during the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.